Pfizer-BioNTech study supports 97% effectiveness of COVID-19 vaccine

By The Science Advisory Board staff writers

March 11, 2021 -- Real-world evidence released by the Israel Ministry of Health demonstrates dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 vaccine.

The data confirm that the vaccine is effective in preventing symptomatic SARS-CoV-2 infection, COVID-19 cases, hospitalizations, severe and critical hospitalizations, and deaths. The data show that two weeks after the second vaccine dose, the vaccine effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease, and death. The analysis found that the vaccine was 94% effective against asymptomatic SARS-CoV-2 infections.

The data were derived from de-identified aggregate Israel Ministry of Health surveillance data collected between January 17 and March 6, 2021, a time when the B.1.1.7 variant was the predominant strain in the country.

Following the authorization for emergency use of the Pfizer-BioNTech COVID-19 vaccine in Israel on December 6, 2020, the Israel Ministry of Health launched a national vaccination program targeting individuals age 16 years or older -- a total of 6.4 million people, representing 71% of the population. Israel regularly collects comprehensive, real-time data on SARS-CoV-2 testing, COVID-19 cases, including date of symptom onset, and vaccination history, through a nationally notifiable disease registry and the national medical record database.

In January, Pfizer and the Israel Ministry of Health entered into a collaboration agreement to monitor the real-world effect of the COVID-19 vaccine. The organizations plan to submit the data to a peer-reviewed journal.

Can a single dose of a vaccine designed as 2 doses be effective?
Researchers suggested that two doses of a COVID-19 vaccine are more protective than a single dose, even if the interdose period is longer than recommended....
Pfizer, BioNTech study 3rd booster of vaccine to protect against variants
Pfizer and BioNTech have started to evaluate the safety and immunogenicity of a third dose of their COVID-19 vaccine BNT162b2 as a booster on immunity...
U.S. opts for 100M more doses of Pfizer-BioNTech COVID-19 vaccine
The U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine
Pfizer, BioNTech vaccine neutralizes SARS-CoV-2 variants in vitro
Pfizer and BioNTech has released results from in vitro neutralization studies of blood sera from individuals vaccinated with its COVID-19 vaccine, providing...

Copyright © 2021 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter